This is a sequential, ascending-dose, multicenter study conducted in patients with refractory
solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of
DCR-STAT3.
Phase:
Phase 1
Details
Lead Sponsor:
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company